Literature DB >> 11961112

Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents.

Maeve Sheehan1, Hector R Wong, Paul W Hake, Vivek Malhotra, Michael O'Connor, Basilia Zingarelli.   

Abstract

Parthenolide is a sesquiterpene lactone used in folk medicine for its anti-inflammatory activity. Recent in vitro studies have shown that this compound inhibits the nuclear factor (NF)-kappaB pathway. This study examines the effect of parthenolide in endotoxic shock in rodents. Endotoxic shock was induced by administration of Escherichia coli endotoxin in rats. Three groups of rats received parthenolide (0.25, 0.5, or 1 mg/kg) 15 min before endotoxin; another group received parthenolide (1 mg/kg) 3 h after endotoxin. In vehicle-treated rats, administration of endotoxin caused severe hypotension, which was associated with a marked hyporeactivity to norepinephrine in ex vivo thoracic aortas. Immunohistochemistry showed positive staining for nitrotyrosine, poly(ADP-ribose) synthetase (PARS) and apoptosis, whereas Northern blot analysis showed increased mRNA expression of inducible nitric-oxide synthase (iNOS) in thoracic aortas. Elevated levels of plasma nitrate/nitrite were also found. Elevated lung levels of myeloperoxidase activity were indicative of infiltration of neutrophils. These inflammatory events were preceded by cytosolic degradation of inhibitor kappaBalpha (IkappaBalpha) and activation of nuclear NF-kappaB in the lung. In vivo pretreatment and post-treatment with parthenolide improved the hemodynamic profile and reduced plasma nitrate/nitrite and lung neutrophil infiltration in a dose-dependent fashion. Vascular hyporeactivity of ex vivo aortas was ameliorated. Treatment with parthenolide also abolished nitrotyrosine formation, PARS expression, and apoptosis and reduced iNOS mRNA content in thoracic aortas. DNA binding of NF-kappaB was inhibited by parthenolide in the lung, whereas degradation of IkappaBalpha was unchanged. In a separate set of experiments, pretreatment or post-treatment with parthenolide significantly improved survival in mice challenged with endotoxin. We conclude that parthenolide exerts beneficial effects during endotoxic shock through inhibition of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961112     DOI: 10.1124/mol.61.5.953

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

Review 1.  The nitric oxide pathway in the cardiovascular system.

Authors:  S Llorens; J Jordán; E Nava
Journal:  J Physiol Biochem       Date:  2002-09       Impact factor: 4.158

2.  Regulation of B cell activating factor (BAFF) receptor expression by NF-ΚB signaling in rheumatoid arthritis B cells.

Authors:  Yun Ju Woo; Bo Young Yoon; Joo Yeon Jhun; Hye Jwa Oh; Se Won Min; Mi La Cho; Sung Hwan Park; Ho Youn Kim; Jun Ki Min
Journal:  Exp Mol Med       Date:  2011-06-30       Impact factor: 8.718

3.  Inhibiting IκBβ-NFκB signaling attenuates the expression of select pro-inflammatory genes.

Authors:  Sarah McKenna; Clyde J Wright
Journal:  J Cell Sci       Date:  2015-04-23       Impact factor: 5.285

4.  Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.

Authors:  Aicha Saadane; Sophia Masters; Joseph DiDonato; Jingfeng Li; Melvin Berger
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

5.  Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome.

Authors:  Christine Juliana; Teresa Fernandes-Alnemri; Jianghong Wu; Pinaki Datta; Leobaldo Solorzano; Je-Wook Yu; Rong Meng; Andrew A Quong; Eicke Latz; Charles P Scott; Emad S Alnemri
Journal:  J Biol Chem       Date:  2010-01-21       Impact factor: 5.157

6.  The NF-κB inhibitory proteins IκBα and IκBβ mediate disparate responses to inflammation in fetal pulmonary endothelial cells.

Authors:  Jen-Ruey Tang; Katherine A Michaelis; Eva Nozik-Grayck; Gregory J Seedorf; Marlena Hartman-Filson; Steven H Abman; Clyde J Wright
Journal:  J Immunol       Date:  2013-02-15       Impact factor: 5.422

Review 7.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

Authors:  Derek S Wheeler; Basilia Zingarelli; William J Wheeler; Hector R Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2009-06

8.  Control of adipose tissue inflammation through TRB1.

Authors:  Anke Ostertag; Allan Jones; Adam J Rose; Maria Liebert; Stefan Kleinsorg; Anja Reimann; Alexandros Vegiopoulos; Mauricio Berriel Diaz; Daniela Strzoda; Masahiro Yamamoto; Takashi Satoh; Shizuo Akira; Stephan Herzig
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

9.  Inhibitors of inflammation and endogenous surfactant pool size as modulators of lung injury with initiation of ventilation in preterm sheep.

Authors:  Noah H Hillman; Suhas G Kallapur; J Jane Pillow; Ilias Nitsos; Graeme R Polglase; Machiko Ikegami; Alan H Jobe
Journal:  Respir Res       Date:  2010-10-29

10.  A pivotal role of endothelial-specific NF-kappaB signaling in the pathogenesis of septic shock and septic vascular dysfunction.

Authors:  Jianqiang Ding; Dongmei Song; Xiaobing Ye; Shu Fang Liu
Journal:  J Immunol       Date:  2009-08-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.